Harpoon Therapeutics Inc (DELISTED) (HARP:DL)
23.01
0.00 (0.00%)
USD |
NASDAQ |
Mar 11, 16:00
Harpoon Therapeutics Research and Development Expense (Annual): 81.39M for Dec. 31, 2022
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2022 | 81.39M |
| December 31, 2021 | 72.12M |
| December 31, 2020 | 52.56M |
| December 31, 2019 | 41.59M |
| Date | Value |
|---|---|
| December 31, 2018 | 26.37M |
| December 31, 2017 | 13.62M |
| December 31, 2016 | 7.778M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
41.59M
Minimum
2019
81.39M
Maximum
2022
61.92M
Average
62.34M
Median
Research and Development Expense (Annual) Benchmarks
| Merck & Co Inc | 30.53B |
| Axonics Inc | 34.89M |
| Johnson & Johnson | 15.08B |
| Boston Scientific Corp | 1.414B |
| Ambrx Biopharma Inc (DELISTED) | 53.31M |